A prognostic model for functional outcome in early rheumatoid arthritis

Journal of Rheumatology

Volumn 33, Issue 8, 2006, Pages 1503-1510

  Bansback, Nick ^a   Young, Adam ^a   Brennan, Alan ^a,b   Dixey, Josh ^a  

^a St Albans City Hospital   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Functional outcome; Health assessment questionnaire; Prognosis; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HEMOGLOBIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; DISEASE ACTIVITY; FEMALE; FUNCTIONAL STATUS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODEL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOGRAPHY; RHEUMATOID ARTHRITIS; SOCIAL STATUS;

ADULT; ALGORITHMS; ARTHRITIS, RHEUMATOID; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NOMOGRAMS; PROGNOSIS; QUESTIONNAIRES; RECOVERY OF FUNCTION; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 33746754717     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Felson D, Anderson J, Meenan R. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. Arthritis Rheum 1990;33:1449-61.
2. Choi EH. Two is better than one? Combination therapy in rheumatoid arthritis [editorial]. Rheumatology Oxford 2004;43:1205-7.
3. Boers M, Verhoeven AC, Markusse HM, et al. Randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
4. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1551-63.
5. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999;130:478-86.
6. Provoo MLL, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight joint scores. Arthritis Rheum 1995;38:44-8.
7. Guidelines for prescribing TNF alpha blockers in adults with rheumatoid arthritis. Working party of the British Society of Rheumatology; 2001. Available from; www.rheumatology.org.uk/guidelines/clinicalguidelines. Accessed April 26, 2006.
8. Scott DL. The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria [editorial]. Arthritis Rheum 2002;46:286-90.
9. Fries JF, Spitz P, Kraines G, Holman H. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
10. Young A, van der Heijde DFM. Can we predict aggressive disease? Ballieres Clin Rheumatol 1997;11:27-48.
11. Brennan P, Harrison B, Barrett E, et al. A simple algorithm to predict the development of radiological erosions in patients with early rheumatoid arthritis: prospective cohort study. BMJ 1996;313:471-6.
12. Drossaers-Bakker KW, Zwinderman AH, Vlieland TP, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002;47:383-90.
13. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002;46:357-65.
14. Young A, Dixey J, Cox N, et al. How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 yr follow up in 781 patients from the Early RA Study (ERAS). Rheumatology Oxford 2000;39:603-11.
15. Wolfe F, Hawley DJ. Measurement of the quality of life in rheumatoid disorders using the EuroQol. Rheumatology Oxford 1997;36:786-93.
16. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology Oxford 1997;36:551-9.
17. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
18. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in persons with rheumatoid arthritis: a 3-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-63.
19. Ramey DR, Fries JF, Singh G, Spilker B. Quality of life and pharmacoeconomics in clinical trials. In: Spilker B, editor. The Health Assessment Questionnaire 1995 - status and review. Philadelphia: Lippincott-Raven; 1996:227-37.
20. Wiles N, Dunn G, Barrett E, Silman A, Symmons D. Associations between demographic and disease-related variables and disability over the first five years of inflammatory polyarthritis. J Clin Epidemiol 2000;53:988-96.
21. Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with RA. J Rheumatol 2002;29:1851-7.
22. Young A, Wilkinson P, Talamo J, et al. Socio-economic factors in the presentation and outcome of early rheumatoid arthritis. Lessons for the health service? Ann Rheum Dis 2000;59:794-9.
23. James D, Young A, Dixey J, et al. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1029 patients followed for 5 years. Rheumatology Oxford 2004;43:369-76.
24. Dixey J, Solymossy C, Young A. Is it possible to predict radiological damage in early RA? J Rheumatol 2004;31 Suppl 69:48-54.
25. Carstairs V. Deprivation indices: their interpretation and use in relation to health. J Epidemiol Community Health 1995;49:s3-8.
26. Arnett FC, Edworthy SM, Bloch DA, et al. The ARA 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-2.
27. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. J Am Med Assoc 1949;140:659-62.
28. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
29. Solymossy C, Dixey J, Utley M, et al. Larsen scoring of digitized X-ray images. Rheumatology Oxford 1999;38:1127-9
30. Tabachnick BG, Fidell LS. Using multivariate statistics. 2nd ed. London; New York: Harper Collins; 1989.
31. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariate prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing bias. Stat Med 1996;15:361-87.
32. Harrell FE. Regression modelling strategies. New York: Springer-Verlag; 2001.
33. Harrell FE. S-Plus and R libraries, functions, and documentation. Available from: http://lib.stat.cmu.edu/S/Harrell/splus.html. Accessed May 5, 2006.
34. Lubsen J, Pool J, van der Does E. A practical device for the application of a diagnostic or prognostic function. Methods Inf Med 1978;17:127-9.
35. Callahan LF, Pincus T. Formal education level as a significant marker of clinical status in rheumatoid arthritis. Arthritis Rheum 1988;31:1346-57.
36. McEntegart A, Morrison E, Capell HA, et al. Effect of social deprivation on disease severity and outcome in patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:410-3.
37. Young A. Early rheumatoid arthritis. Rheum Dis Clin North Am 2005;31:659-79.
38. Scott DL, Pugner K, Kaarela K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology Oxford 2000;39:122-32.
39. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
40. Wyatt JC, Altman DG. Commentary: Prognostic models: clinically useful or quickly forgotten? BMJ 1995;311:1539-41.
41. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;9:453-73.
42. Visser H, Hazes JM. Prognostics. Best Pract Res Clin Rheumatol 2003;17:403-14.
43. Garwood W. The early RA network. Musculoskeletal Care 2004;2:240-4.
44. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases. Ann Rheum Dis 2003;62 Suppl II:ii2-9.